Cancer is a condition where cells in a specific part of body grow and reproduceuncontrollably. The purpose of this study is to assess adverse events and change indisease activity when ABBV-400 is given in combination with Fluorouracil, Folinic Acid,and Bevacizumab to adult participants to treat unresctable metastatic colorectal cancer.ABBV-400 is an investigational drug being developed for the treatment of unresectablemetastatic colorectal cancer. Fluorouracil, folinic acid, and bevacizumab is an drugapproved for the treatment of unresectable metastatic colorectal cancer. Study doctorsput the participants in groups called treatment arms. Each treatment arm receives adifferent dose of ABBV-400 in combination with fluorouracil, folinic acid, andbevacizumab (FFB) in escalating doses on two different schedules (safety lead in),followed by low or high doses of ABBV-400 in combination with FFB or fluorouracil,folinic acid, irinotecan, and bevacizumab (standard of care [SOC]) [dose optimizat
Cancer is a condition where cells in a specific part of body grow and reproduceuncontrollably. The purpose of this study is to assess adverse events and change indisease activity when ABBV-400 is given in combination with Fluorouracil, Folinic Acid,and Bevacizumab to adult participants to treat unresctable metastatic colorectal cancer.ABBV-400 is an investigational drug being developed for the treatment of unresectablemetastatic colorectal cancer. Fluorouracil, folinic acid, and bevacizumab is an drugapproved for the treatment of unresectable metastatic colorectal cancer. Study doctorsput the participants in groups called treatment arms. Each treatment arm receives adifferent dose of ABBV-400 in combination with fluorouracil, folinic acid, andbevacizumab (FFB) in escalating doses on two different schedules (safety lead in),followed by low or high doses of ABBV-400 in combination with FFB or fluorouracil,folinic acid, irinotecan, and bevacizumab (standard of care [SOC]) [dose optimizat
